Edwards Lifesciences Corp (EW)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,548,100 | 1,598,100 | 1,767,400 | 1,702,000 | 916,700 |
| Revenue | US$ in thousands | 5,439,500 | 6,004,800 | 5,382,400 | 5,232,500 | 4,386,300 |
| Pretax margin | 28.46% | 26.61% | 32.84% | 32.53% | 20.90% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $1,548,100K ÷ $5,439,500K
= 28.46%
The pretax margin of Edwards Lifesciences Corp has shown an upward trend from 2020 to 2022, indicating improved efficiency in generating profits before accounting for taxes. In 2020, the pretax margin was 20.90%, which increased to 32.53% in 2021 and further to 32.84% in 2022. This significant improvement suggests effective cost management and revenue growth during these years.
However, in 2023, the pretax margin decreased to 26.61%, indicating a slight decline in profitability efficiency. In 2024, there was a moderate recovery as the pretax margin rose to 28.46%. Overall, although there was a slight fluctuation in the pretax margin over the years, Edwards Lifesciences Corp has generally maintained a strong profitability performance, with margins consistently above 20%.
Peer comparison
Dec 31, 2024